Methods for diagnosing and treating pediatric neoplasms
View Patent ↗The present invention provides a method for determining whether a subject has a pediatric neoplasm. The present invention further provides a method for assessing the efficacy of therapy to treat a pediatric neoplasm in a subject who has undergone or is undergoing treatment for a pediatric neoplasm. In addition, the present invention provides a method for assessing the prognosis of a subject who has a pediatric neoplasm. Finally, the present invention provides a method for treating a pediatric neoplasm in a subject in need of treatment thereof.
1. A method for determining whether a subject with neuroblastoma has a stage I, stage II, stage III, or stage IV neuroblastoma, the method comprising:
a) obtaining from a subject diagnosed with neuroblastoma a sample comprising neuroblastoma cells from a solid tumor; and
b) detecting Id2 protein in intact cells in the sample using an antibody, or Fab or F(ab′) 2 fragment thereof, that is reactive with Id2 protein,
wherein a sample with an Id2 labeling index of about 5% of the cells in the sample indicates that the neuroblastoma is a stage I neuroblastoma;
wherein a sample with an Id2 labeling index of about 30% of the cells in the sample indicates that the neuroblastoma is a stage II neuroblastoma;
wherein a sample with an Id2 labeling index of about 35% of the cells in the sample indicates that the neuroblastoma is a stage III neuroblastoma; and
wherein a sample with an Id2 labeling index of about 50% of the cells in the sample indicates that the neuroblastoma is a stage IV neuroblastoma.
2. The method of claim 1 , wherein the antibody or fragment thereof is labeled with a detectable marker.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 1 , wherein the subject is less than 1 year old.
5. A method for determining whether a subject with neuroblastoma has a stage IV neuroblastoma, the method comprising:
a) obtaining from a subject diagnosed with neuroblastoma a sample comprising neuroblastoma cells from a solid tumor; and
b) detecting Id2 protein in intact cells in the sample,
wherein samples with detectable Id2 protein in the nuclei of 25% or more tumor cells are determined to be stage IV neuroblastoma.
6. The method of claim 5 , wherein the subject is a human.
7. The method of claim 5 , wherein the subject is less than 1 year old.
8. The method of claim 5 , wherein the Id2 protein is detected using an antibody, or Fab or F(ab′) 2 fragment thereof, that is reactive with Id2 protein, and the antibody or fragment thereof is labeled with a detectable marker.
9. A method for predicting survival in a subject with neuroblastoma, the method comprising:
a) obtaining from a subject diagnosed with neuroblastoma a sample comprising neuroblastoma cells from a solid tumor;
b) detecting Id2 protein in intact cells in the sample; and
c) predicting survival of the subject;
wherein subjects with sample cells positive for Id2 show decreased likelihood of survival compared to subjects with sample cells negative for Id2.
10. The method of claim 9 , wherein subjects with sample cells positive for Id2 protein show a lower than 50% chance of survival at 20 months or more after diagnosis.
11. The method of claim 9 , wherein subjects with sample cells negative for Id2 protein show a greater than 80% likelihood of survival at 20 months or more after diagnosis.
12. The method of claim 9 , wherein the subject is a human.
13. The method of claim 9 , wherein the subject is less than 1 year old.
14. The method of claim 9 , wherein the Id2 protein is detected using an antibody, or Fab or F(ab′) 2 fragment thereof, that is reactive with Id2 protein, and the antibody or fragment thereof is labeled with a detectable marker.